Personalis EBITDA Margin 2018-2026 | PSNL
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Personalis (PSNL) over the last 10 years. The current EBITDA margin for Personalis as of June 30, 2026 is .
| Personalis EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2026-06-30 | $0.07B | $-0.11B | -160.29% |
| 2026-03-31 | $0.06B | $-0.10B | -153.97% |
| 2025-12-31 | $0.07B | $-0.08B | -118.84% |
| 2025-09-30 | $0.07B | $-0.07B | -107.25% |
| 2025-06-30 | $0.08B | $-0.06B | -79.01% |
| 2025-03-31 | $0.09B | $-0.06B | -67.82% |
| 2024-12-31 | $0.09B | $-0.06B | -69.77% |
| 2024-09-30 | $0.09B | $-0.07B | -74.16% |
| 2024-06-30 | $0.08B | $-0.08B | -102.47% |
| 2024-03-31 | $0.08B | $-0.09B | -121.33% |
| 2023-12-31 | $0.07B | $-0.10B | -136.49% |
| 2023-09-30 | $0.07B | $-0.11B | -152.11% |
| 2023-06-30 | $0.07B | $-0.10B | -152.94% |
| 2023-03-31 | $0.07B | $-0.11B | -155.07% |
| 2022-12-31 | $0.07B | $-0.11B | -163.08% |
| 2022-09-30 | $0.07B | $-0.10B | -137.68% |
| 2022-06-30 | $0.08B | $-0.09B | -113.16% |
| 2022-03-31 | $0.08B | $-0.07B | -91.25% |
| 2021-12-31 | $0.09B | $-0.06B | -66.28% |
| 2021-09-30 | $0.09B | $-0.05B | -60.00% |
| 2021-06-30 | $0.08B | $-0.04B | -51.81% |
| 2021-03-31 | $0.08B | $-0.04B | -47.50% |
| 2020-12-31 | $0.08B | $-0.04B | -46.15% |
| 2020-09-30 | $0.08B | $-0.03B | -39.47% |
| 2020-06-30 | $0.07B | $-0.03B | -36.99% |
| 2020-03-31 | $0.07B | $-0.02B | -31.43% |
| 2019-12-31 | $0.07B | $-0.02B | -27.69% |
| 2019-06-30 | $0.04B | $-0.01B | -19.05% |
| 2019-03-31 | $0.04B | $-0.01B | -25.71% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |